[18F]DCFPyL PET/CT for Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, (68) Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of (18) F-labeled agents. Among others, [ (18) F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [ (18) F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this (18) F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [ (18) F]DCFPyL in various clinical settings for men with PC.

Automated summary

Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). [ (18) F]DCFPyL has been widely utilized for staging, restaging, and change in management, and has shown promise for response assessment in patients under specific treatments.